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Whipple’s disease was described in 1907 and was designated “intestinal lipodystrophy,” despite the detection of bacteria in
1 specimen. This finding was later substantiated by the success of antibiotic therapy, which resulted in dramatic clinical
responses, and by use of electron microscopy, which detected monomorphic bacilli in affected tissues. Many attempts at
culture failed, and these bacteria were characterized as actinomycetes for the first time by means of broad-range 16S rDNA
amplification and molecular phylogenetic methods. The name “Tropheryma whippelii” was proposed for this bacterium.
Whipple’s disease is a systemic disease that affects many organ systems, producing protean manifestations. This article
summarizes recent developments with regard to this topic as well as unanswered questions regarding the pathogenesis and
acquisition of infection, the biology and ecology of the organism, the clinical spectrum of disease, diagnosis of the disease,
and therapy.
In 1907, George H. Whipple described autopsy findings for a
36-year-old patient who had a 5-year history of an illness that
was dominated by arthritis, fever, chronic cough, weight loss,
and diarrhea [1]. He observed deposits of fat and fatty acids
in the intestinal mucosa and mesenteric lymph nodes; he as-
signed the term “intestinal lipodystrophy” to this disease. In
1961, bacteria were detected in affected tissues by means of
electron microscopy [2, 3]. However, subsequent attempts to
cultivate these bacteria failed. In the early 1990s, characteri-
zation on the basis of molecular phylogeny was achieved by
means of broad-range bacterial rDNA PCR analysis [4, 5]. A
newly acquired 16S rDNA sequence revealed a phylogenetic
relationship between the bacterium and the actinomycetes, al-
though there was no known close relative, and the name Tro-
pheryma whippelii was proposed [5]. Whipple’s disease is con-
sidered to be rare. In the only published monograph on this
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entity, Dobbins [6] compiled information from 696 cases avail-
able through 1986.
CLINICAL MANIFESTATIONS
Whipple’s disease is a systemic disease with a propensity for
affecting the gastrointestinal tract [6]. Its clinical manifestations
have been compiled and extensively discussed in several case
series and reviews [6–11]. Intestinal manifestations are most
commonly reported; these help to define what is known as
“classical” Whipple’s disease, which includes weight loss, di-
arrhea, and abdominal pain. Intestinal symptoms are often pre-
ceded by arthralgias for several years (up to 30 years). Abdom-
inal and peripheral lymphadenopathies are also common.
Extraintestinal disease often involves the brain and the heart.
Endocarditis, myocarditis, and pericarditis have all been re-
ported. Symptomatic Whipple’s disease of the CNS can occur
at the time of initial diagnosis and can accompany intestinal
manifestations, but it is more commonly reported as the cause
of disease relapse during or after antibiotic treatment [6, 12].
Relapses in the CNS pose a serious challenge to clinical man-
agement, because they can be refractory to antibiotic treatment.
Cases of primary neurological disease without detectable in-
testinal involvement have been reported [13, 14]. Ocular in-
volvement (e.g., uveitis) has been reported, including cases in
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Table 1. Diagnostic methods for Whipple’s disease.
Method Sample types Comments Reference
Routine histologic analysis
(with PAS staining)
Tissues (e.g., intes-
tinal, brain, etc.)
Standard method; PAS-positive, diastase-resistant,
non–acid-fast inclusions in macrophages are highly
suggestive
[6, 25]
Cytological analysis (with
PAS staining)
Body fluids (e.g.,
CSF, joint fluid,
vitreous fluid)
Body fluids should be fresh (<1 h) [6, 15, 26, 27]
Electron microscopy Tissues, body fluids Recommended for confirmation of routine histopathologic
analysis; time consuming; shows bacteria of typical size
and shape
[6, 28, 29]
PCR analysis Tissues, body fluids Alternative test for confirmation; available in research and ref-
erence laboratories and few commercial laboratories
[5, 19–24]
NOTE. PAS, periodic acid–Schiff.
patients who do not have grossly apparent intestinal disease [6,
15]. “Exotic,” or rare, manifestations of Whipple’s disease in-
clude prosthetic joint infection [16], spondylodiskitis [17], and
extreme insomnia [18].
DIAGNOSIS
Histopathologic or cytological analysis by means of periodic
acid–Schiff (PAS) staining are the standard methods used for
diagnosis of Whipple’s disease. The characteristic feature of the
disease is the presence of macrophages with intracellular in-
clusions that react with the PAS stain and appear magenta (i.e.,
sickleform particle–containing cells), especially in the lamina
propria of the small intestine. The inclusions reflect accumu-
lations of degraded cell wall and intact bacteria. Electron mi-
croscopy has been recommended to confirm histopathologic
diagnoses, especially in extraintestinal sites [6].
Diagnostic PCR assays for T. whippelii are increasingly being
used to establish and confirm the diagnosis of Whipple’s disease
[19–24]. Although data on clinical sensitivity and specificity
are scarce and difficult to acquire, well-optimized PCR assays
are capable of detecting as few as 10 copies of the 16S rRNA
gene per reaction, and PCR analysis of histologically positive
specimens almost always yields positive results [19, 20]. There
is still room for improvement of PCR testing and improvement
in the selection of optimal specimen types. For example, not
all PCR assays have been validated with thorough measurement
of performance characteristics and identification of amplified
products. An overview of diagnostic methods is given in table
1.
Despite the apparent rarity of Whipple’s disease, the fact that
it can occur in the absence of “classical” intestinal manifesta-
tions emphasizes the importance of considering the diagnosis
in patients with atypical presentations. Certainly, Whipple’s dis-
ease should be suspected in patients with weight loss, diarrhea,
arthralgias, and abdominal pain or in patients with arthralgias,
fever, and minor gastrointestinal complaints [6]. In these cases,
upper gastrointestinal endoscopy is indicated, and several bi-
opsy specimens from the lower duodenum should be obtained
(because patchy disease involvement is possible) and subjected
to histopathologic examination. In his monograph, Dobbins
[6] provided a list of additional clinical settings in which Whip-
ple’s disease should be suspected. Dementia with no apparent
cause, or chest pain and chronic cough with lung infiltrates
that simulate sarcoidosis are examples of syndromes on this
list. Enlarged intra-abdominal and peripheral lymph nodes that
are hypodense on CT scans and hypoechoic on ultrasonograms,
as well as skin hyperpigmentation that is not related to adrenal
dysfunction or hyperbilirubinemia, may provide diagnostic
hints [6]. In cases of suspected extraintestinal Whipple’s disease,
it is advisable to obtain specimens from the affected anatomic
sites, in addition to intestinal biopsy specimens. This strategy
applies to initial presentations with minimal or no apparent
intestinal involvement [15, 27]; in addition, it applies to pa-
tients after treatment of Whipple’s disease, when either clinical
findings persist or new atypical presentations occur, as is il-
lustrated by a case of extreme insomnia occurring 8 years after
diagnosis and treatment of intestinal disease [18].
THERAPY AND MONITORING
There are still no randomized, double-blind trials of different
antibiotic regimens upon which to base recommendations for
the treatment of Whipple’s disease. On the basis of the com-
bined observations from many case reports [6], several patient
series [9–11], and retrospective analyses [30, 31], the therapy
most commonly associated with clinical success is initial iv
treatment with penicillin G and streptomycin, or a third-gen-
eration cephalosporin, followed by administration of co-tri-
moxazole for at least 1 year (table 2). The main objectives of
treatment of Whipple’s disease are to eradicate primary (usually
intestinal) disease and to prevent relapse. Considering the tro-
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Table 2. Recommended therapy for Whipple’s disease.
Timing First choice Alternative
Initially (first 10–14 days) Pen G (6–24 million U iv q.d.) plus Stm (1 g im q.d.) or
third-generation cephalosporin (e.g., Ctri 2 g iv q.d.)
TMP-SMZ (160 mg/800 mg po b.i.d.)
Long term (∼1 year) TMP-SMZ (160 mg/800 mg po b.i.d.) Dox (100 mg po b.i.d, Cfix (400 mg
po b.i.d.), or Pen V potassium
(500 mg po q.i.d.)
NOTE. Dox, doxycycline; Cfix, cefixime; Ctri, ceftriaxone; Pen, penicillin; Stm, streptomycin; TMP-SMZ, trimethoprim-sulfamethoxazole.
pism of T. whippelii for the CNS and, thus, the threat posed
by relapses in the CNS [26, 30], early use of drugs with good
penetration of the blood-brain barrier is important.
Well-established protocols for patient follow-up during and
after therapy are also lacking. Routine periodic assessment of
sites of frequent disease involvement, such as the abdominal
lymph nodes, cardiovascular system, and CNS, would be pru-
dent. PAS-positive macrophages undergo morphological
changes but persist for up to several years [25]; intact bacterial
cells (with status determined by means of electron microscopy)
are shorter lived, disappearing after a few months [28]. Positive
results of PCR analysis of intestinal specimens (results indicate
bacterial DNA) convert to negative results usually within 1–12
months after initiation of therapy [19].
One study suggested that PCR analysis of intestinal speci-
mens may be useful for monitoring the efficacy of therapy [20],
whereas another investigation found that some patients for
whom the results of PCR analysis of intestinal samples are
negative develop relapses in the CNS [19]. Cytological or PCR-
based examinations of CSF may be useful for both initial
assessment and monitoring of the development of CNS com-
plications during therapy [26]. At present, there are no solid
data that one can use to decide when antibiotic therapy should
be terminated, but therapy with an overall duration of at least
1 year is considered necessary [30, 31]. The currently available
data, albeit scant, suggest that posttreatment progression and
relapse of disease are caused by the original infecting bacterial
strain (see below), rather than by reinfection by a different strain.
IS WHIPPLE’S DISEASE UNDERDIAGNOSED?
The question of whether a disease or infection has been un-
derdiagnosed naturally arises when new, more-sensitive diag-
nostic methods become available. Whipple’s disease has tra-
ditionally been recognized by its “classical” clinical features.
One would expect that this circumstance imposes a bias on the
recognition and description of the full spectrum of disease
manifestations. For example, Whipple’s disease was retrospec-
tively diagnosed in a specimen from 1895 that was stored at
the Westminster Museum in London, by means of the newly
available PAS stain [32]. The introduction of endoscopy in the
1970s, used in combination with PAS staining (which was in-
troduced in the 1940s), led to the diagnosis of cases with in-
testinal pathology but “atypical” symptoms. By use of other
diagnostic procedures (e.g., radiographically guided tissue bi-
opsy or PCR analysis), cases of extraintestinal disease accom-
panied by minimal or no apparent intestinal involvement have
been diagnosed [15, 17, 27, 33]. These diagnosed cases might
have been missed before the availability of these methods.
At the same time, Whipple’s disease is considered to be in-
variably fatal when it is not treated with antibiotics [6]. If a
significant number of cases were unrecognized and untreated,
one might expect some of them to be discovered at autopsy;
however, this is not a common event. It is possible that spon-
taneous remission or resolution of disease occurs, and it is
conceivable that patients with unsuspected disease are cured
when they undergo short courses of antibiotic therapy for other
complaints. In this context, the observation by Fleming et al.
[9] of a case of long-term remission after a 5-day course of
antibiotic therapy is intriguing. Furthermore, it has been sus-
pected that the frequent use of antibiotics in general medical
practice, in dosages and durations inadequate for cure, may
have altered the age of presentation with Whipple’s disease
during the past several decades [34].
Overall, it seems unlikely that a significant number of ad-
vanced cases of Whipple’s disease go undiagnosed; however, it
remains unclear whether this theory holds true for less severe
cases and for those that may be cured by short courses of
antibiotics. Over a period of 30 years, Dobbins [6] noted a
relatively stable incidence of Whipple’s disease, with a ratio of
1 published case to every 4 unpublished cases. Given how little
we know about the natural habitat of the organism (see the
Pathogenesis and Acquisition of Infection section) and the
route(s) of transmission to humans, it is even more unclear
whether asymptomatic, transient, or persistent infections in
privileged anatomic compartments (those that are usually free
of microorganisms) are common occurrences.
MICROBIOLOGY
Electron microscopy of tissue specimens from patients with
Whipple’s disease reveals uniformity in bacterial size (0.2–
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mm) and shape [6, 29]. The bacteria are sur-0.25 3 1–2.5
rounded by an unusual outer membrane not found in other
gram-positive bacteria and unlike those seen in gram-negative
bacteria: it appears to lack lipopolysaccharide. Some investi-
gators have concluded that this membrane may be of host
origin [29]. Phylogenetic analysis based on 16S rDNA sequence
amplification with broad-range bacterial PCR primers revealed,
for the first time, that the bacterium is a member of the ac-
tinomycetes [4, 5]; a subsequent analysis performed 4 years
later, in which an expanded 16S rRNA sequence database was
used, placed the organism between the genus Cellulomonas and
a rare group of actinomycetes with group B peptidoglycan [35],
with relatively distant relationships (16S rRNA similarity,
91%–92%) to members in either group. As a result, the lack
of a known close relative prevents meaningful inferences of
physiology and function for T. whippelii from well-studied cul-
tivated members of this bacterial division.
Attempts to cultivate the Whipple’s disease bacterium have
had a troubled history; many attempts have been undertaken,
and the “successful” isolation of a causative agent in a number
of reports turned out to be nonreproducible [6]. One notable
report by Schoedon et al. [36] was published in 1997. Heart
valve tissue specimens obtained from 2 infected patients were
inoculated onto human macrophages that had been treated with
IL-4 in cell culture. This treatment impairs the microbicidal
killing mechanisms of macrophages and facilitates the growth
of intracellular microorganisms. Accumulation of PAS-positive
intracellular inclusions and the persistence of PCR-amplified
product after cell passage were interpreted as being indicative
of growth of T. whippelii. However, these results have not been
reproduced by other researchers (Maiwald and Relman, un-
published data; [37]). A nonvalidated PCR assay was used by
Schoedon et al. [36], and the PAS reagent stains bacterial cell
wall components even in advanced stages of degradation [6, 25].
Raoult et al. [38] reported another promising set of findings.
An aortic valve tissue sample from a patient with endocarditis
was inoculated onto a human fibroblast cell line, without special
pretreatment of the cells (e.g., deactivation by cytokines). After
65 days of incubation, a cytopathic effect was observed, and
microorganisms were seen by means of several staining pro-
cedures, including PAS staining. Fibroblast culture material was
passaged 7 times, and after 285 days, a 3750-cm2 infected cell
monolayer was obtained from an initial inoculum of 1 cm2 of
cells. Several stains showed bacteria, and results of PCR analysis
were positive for T. whippelii after each passage. The doubling
time of the bacteria was estimated to be 18 days under these
particular growth conditions, which is slower than that of My-
cobacterium leprae in a mouse model (12 days). Immunoflu-
orescence staining that used samples of the patient’s serum as
well as murine polyclonal antibodies raised against cultured
material revealed bacteria in and on fibroblasts and in the orig-
inal heart valve. Serological tests were also performed using
cultured material as antigen. Elevated titers of IgM antibody
were detected in 7 of 9 serum samples from different patients
with Whipple’s disease and in 3 of 40 serum samples from
controls, whereas titers of IgG antibody were elevated for all 9
patients with Whipple’s disease and for 29 of 40 controls.
Taken together, there is good evidence that these investigators
have propagated T. whippelii ex vivo. However, the story is not
yet complete: there is no documentation, by use of a quanti-
tative method (e.g., quantitative PCR analysis), of an increase
in bacterial numbers; this propagated organism did not orig-
inate from a patient with typical or “classical” Whipple’s dis-
ease; and nothing is currently known about whether the de-
scribed culture conditions reflect the optimal growth conditions
for this organism. Although the reported doubling time renders
this culture method impractical for routine laboratories, this
report may constitute an important step toward the ultimate
goal of routine propagation of T. whippelii in the laboratory.
Basic epidemiological tasks, such as tracking routes of in-
fection and determining linkage between cases, require bacterial
strain identification and discrimination. The first step toward
strain typing of T. whippelii has been achieved using the bac-
terial 16S–23S rRNA intergenic spacer sequence. This sequence
was initially determined from a specimen from 1 patient with
Whipple’s disease [35]; variability of the spacer sequence was
addressed in subsequent studies [39–41]. One study [39] found
homogeneity in the spacer sequences in 9 Swiss individuals;
another study by the same group of investigators [40] found
3 different spacer types in 28 individuals whose geographic
locations were not specified. A third study [41] found 5 dif-
ferent spacer types in 56 specimens from 43 patients from 4
countries; this study described the most common types, “1”
and “2,” in a similar ratio (∼1:2) in patients from the United
States, Germany, and Switzerland. Specimens from different
anatomic sites generally yielded the same spacer types in in-
dividual patients, which supports the concept of systemic dis-
semination of a single bacterial clone [41]. However, 1 intestinal
biopsy sample from 1 patient contained 2 sequence types, which
raised, for the first time, the possibility of double infection with
T. whippelii [41]. Despite these efforts, the 16S–23S rRNA in-
tergenic spacer sequence with its 6 known variant types may
not be adequate for discrimination between T. whippelii strains
at a clinically relevant level. A more variable genetic locus or
set of loci needs to be identified for this purpose.
PATHOGENESIS AND ACQUISITION OF
INFECTION
Important unresolved issues pertaining to the pathogenesis of
Whipple’s disease include the source and route of infection and
the possibility of differential host susceptibility. Very little is
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presently known regarding these issues. Because of the prom-
inence of intestinal manifestations, an oral route of acquisition
is assumed [6]. The highest concentration of visible bacilli is
usually found within the lamina propria of the small intestine,
subjacent to the epithelial basement membrane [28]. It seems
likely that bacilli translocate across or between the epithelial
cells from the luminal to the basal zone, cross the basement
membrane, and then elicit a macrophage-predominant re-
sponse. Despite the recent report describing the propagation
of T. whippelii in vitro with use of eukaryotic cells [38], intact
and dividing bacteria are most often found in vivo outside of
host cells [29]. Thus, this microbe may actually be an extra-
cellular pathogen, and the keys to its optimal cultivation may
be found within the microenvironment of the lamina propria.
Transient (during active disease) as well as persistent (after
therapy) abnormalities of immune function have been de-
scribed in patients with Whipple’s disease [6, 42]; the persistent
abnormalities are presumed to serve as predisposing factors.
However, precise immune defects have not been adequately
defined. The notion of preexisting host impairment is sup-
ported by the observation of opportunistic infections in some
patients with Whipple’s disease [43]. One patient appears to
have benefited from adjuvant IFN-g treatment [44]. T. whippelii
DNA has also been detected in a patient with AIDS [45]. How-
ever, the issue is complicated by the common occurrence of
malabsorption and malnutrition in patients with AIDS and
their consequences for immune cell function. Further reports
on the detection of T. whippelii in patients with AIDS have not
appeared, but detection of this bacterium may have been missed
by routine diagnostic examinations. Taken together, if there is
a host genetic defect, the phenotype is relatively subtle.
Two recent publications reported PCR-based detection of T.
whippelii DNA in specimens from persons with no signs of
Whipple’s disease. In one series, results of tests of saliva samples
from 14 (35%) of 40 apparently healthy persons were positive
[46] for T. whippelii; in another series, results of PCR analysis
of intestinal biopsy or gastric juice samples were positive for
14 (13%) of 105 patients undergoing endoscopy for reasons
other than suspected Whipple’s disease [47]. These investigators
speculated that T. whippelii is a commensal of the normal hu-
man gastrointestinal tract. On the other hand, several published
series found no evidence for T. whippelii DNA in control in-
testinal biopsy specimens by use of PCR analysis [19–22]. Al-
though additional data on T. whippelii DNA in saliva are not
available, combined results from several institutions would ar-
gue against the human small intestine being a significant res-
ervoir for T. whippelii [48].
In the analysis by Dobbins [6], farmers and carpenters were
the professional groups most commonly affected by Whipple’s
disease. An epidemiological study in Germany [34] found a
relatively homogeneous geographic and temporal distribution
of cases. Most of the known phylogenetic relatives of T. whip-
pelii, especially those on closer branches of the evolutionary
“tree,” are environmental organisms or plant pathogens [35].
These features point to a potential environmental habitat for
T. whippelii and to the source of infection. Indeed, the results
of a PCR-based search in 5 different sewage treatment plants,
representing rich polymicrobial communities outside the hu-
man host, revealed that 25 of 38 samples were positive for T.
whippelii [49].
CONCLUSIONS AND PERSPECTIVES
The Whipple’s disease bacterium—recalcitrant to cultivation,
encased by a thick and unique cell wall, and without known
close relatives—has been slow to reveal its secrets. However,
the past 10 years have been marked by a number of important
findings. The organism has been identified and characterized
at a molecular level, and a reliable diagnostic signature has been
defined [4, 5]. The first stages of a bacterial typing scheme have
been established [35, 40, 41]. A recent report suggests that
propagation of the bacterium in vitro may be possible [38].
From either a propagated organism in ex vivo culture or by
use of broad-range amplification methods with clinical speci-
mens, we are certain to acquire a great deal of additional geno-
typic and phenotypic information about this bacterium during
the next 5 years, leading to tools for serological diagnosis, de-
velopment of new therapeutics, and insights into disease
pathogenesis.
Genomics and a rapidly accumulating set of associated tech-
niques are likely to yield a more complete genomewide per-
spective on the capabilities, gene responses, and deficiencies of
this bacillus. As has been the case with other actinomycetes,
we can expect to find unusual metabolic pathways, biosynthetic
products of relevance to virulence (and of possible use as novel
drugs), and clues about its natural environment. Sensitive and
specific detection methods that are currently available can and
will be used to define the preferred habitats of T. whippelii
within and outside of the human host. For example, fluorescent
in situ hybridization techniques can be used to map the ana-
tomic distribution of T. whippelii rRNA in affected tissues. As
observed with Legionella pneumophila, initial laboratory growth
conditions (charcoal-yeast extract agar) may prove to be quite
distinct from those that the organism has selected in the natural
world (within free-living amoebae). Finally, a wide variety of
tools and data sets will permit a reassessment of host suscep-
tibility to Whipple’s disease.
The Human Genome Project, by facilitating comprehensive
surveys of host gene polymorphisms and variant gene re-
sponses, will provide significant contributions to the study of
infectious disorders such as Whipple’s disease, for which rel-
evant laboratory models of disease are unavailable. It is a safe
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bet that, during the next 10 years, many of the remaining
mysteries about this disease and disease agent will be explained,
and, with these explanations, profoundly important biological
principles will be established
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